# Pharmacological Modulation of DNA Damage Response Pathways in Cancer Therapy

**Ujjwal [1*], Dr. Pushpendra Kumar [2], Kajal Varshney[3], Md. Faiyaz[4]**

[1,3,4]Department of Pharmacology, Faculty of Pharmacy, UPUMS, Saifai, Etawah, Uttar Pradesh, India

[2] Department of Pharmacology, Faculty of Pharmacy, UPUMS, Saifai, Etawah, Uttar Pradesh, India

**Corresponding author**: Ujjwal Diwakar
**Email**: ujjawal.diwakar2100@gmail.com
**Doi**: 10.5281/zenodo.16605844
**Received**: 25 June 2025
**Accepted**: 05 July2025

**Abstract**

In cancer treatment, scientists are exploring ways to influence how cells respond to DNA damage. Cancer cells often have flaws in their DNA repair systems, which makes them more vulnerable to treatments that target those weaknesses. One approach is using medications that interfere with these repair mechanisms, effectively leading to the destruction of cancer cells while sparing healthy ones.

For example, drugs known as PARP inhibitors, (such as olaparib and niraparib) block a key repair process in cells. This is especially effective in cancers with mutations in the BRCA genes, making them more susceptible to damage.

Combining these therapies with immunotherapy or traditional chemotherapy is also being studied to enhance effectiveness. However, there are challenges, including resistance to treatment, potential side effects, and identifying the right patients who will benefit most.

The DNA damage response (DDR) plays a pivotal role in preserving genomic integrity and preventing malignant transformation. Recent advances have underscored the therapeutic potential of pharmacologically targeting DDR pathways to exploit cancer-specific vulnerabilities. We highlight how these agents induce synthetic lethality in tumors with homologous recombination deficiency and replication stress, while also discussing combination approaches with chemotherapy, radiotherapy, and immunotherapy. Biomarker-driven strategies for patient selection, challenges in resistance development, and emerging trends in personalized treatment paradigms are also reviewed. By analyzing recent preclinical and clinical studies, this article provides an updated framework for leveraging DDR modulation as a precision oncology strategy, emphasizing both current challenges and future opportunities.

**Keywords** - DNA Damage Response, PARP Inhibitors, Synthetic Lethality, Cancer Therapy, DDR Inhibitors, Biomarkers, Precision Oncology

## 1. Introduction

### 1.1 Background

Cancer is fundamentally a disease driven by genomic instability, a hallmark that promotes malignant transformation and therapeutic resistance [1]. To counteract genomic insults, eukaryotic cells rely on an intricate DNA damage response (DDR) network, encompassing damage sensing, signaling, and repair pathways [2]. Central to this system are processes such as homologous recombination (HR), non-homologous end joining (NHEJ), nucleotide excision repair (NER), mismatch repair (MMR), and base excision repair (BER) [3].

### 1.2 DDR Defects in Cancer

In many cancers, DDR components are disrupted—either through genetic mutations, epigenetic silencing, or post-translational modifications—resulting in vulnerabilities that can be therapeutically exploited [4,5]. These alterations contribute to clonal evolution, tumor heterogeneity, and therapeutic resistance [6].

### 1.3 Synthetic Lethality and DDR-Targeted Therapies

The concept of synthetic lethality has revolutionized DDR-targeted cancer therapy. For instance, PARP inhibitors (PARPi) are a paradigm-shifting treatment for tumors harboring BRCA1/2 mutations and other HR deficiencies [7]. This approach has expanded to include inhibitors of ATR, ATM, CHK1, WEE1, and DNA-PK, offering new avenues to induce selective cytotoxicity in cancer cells [8].

### 1.4 Objectives of the Review

This review provides a comprehensive examination of DDR pathways, their role in tumorigenesis, and how pharmacological modulation of DDR can enhance treatment efficacy. Key DDR inhibitors in clinical practice and trials, combination regimens to overcome resistance, and challenges in biomarker identification for patient selection are explored [9]. Finally, emerging directions, including artificial intelligence-driven biomarker discovery and next-generation DDR modulation strategies, are discussed [10].

## 2. Mechanistic Overview of DDR Pathways

The DNA damage response (DDR) encompasses multiple repair mechanisms, each specialized to recognize and resolve distinct types of genomic lesions. These pathways work in concert to maintain genome stability and ensure cell viability.

### 2.1 Base Excision Repair (BER)

BER primarily addresses small, non-helix-distorting base lesions—such as oxidized or alkylated bases—caused by endogenous and exogenous stressors. The process is initiated by DNA glycosylases that excise damaged bases, followed by AP endonuclease-mediated backbone cleavage, and gap-filling by DNA polymerase β [11].

### 2.2 Nucleotide Excision Repair (NER)

NER repairs bulky, helix-distorting lesions—including UV-induced thymine dimers and chemical adducts. Damage recognition involves XPC-RAD23B in global genomic NER (GG-NER) and RNA polymerase II stalling in transcription-coupled NER (TC-NER) [12,13].

### 2.3 Mismatch Repair (MMR)

MMR corrects replication errors like base-base mismatches and small insertion/deletion loops. Key components include the MSH2–MSH6 (MutSα) complex for recognition and MLH1–PMS2 (MutLα) for repair initiation [14,15].

### 2.4 Homologous Recombination (HR)

HR is a high-fidelity repair pathway for double-strand breaks (DSBs), activated during S and G2 phases. It relies on the MRN complex for resection, RAD51-mediated strand invasion, and synthesis using the sister chromatid as a template [16,17].

### 2.5 Non-Homologous End Joining (NHEJ)

NHEJ repairs DSBs by direct ligation, active throughout the cell cycle. Ku70/80 binds DNA ends, recruits DNA-PKcs, and promotes ligation by XRCC4–DNA ligase IV. While efficient, NHEJ is error-prone, causing small indels [18].

**Table 1: Overview of Major DDR Pathways**

| S. No. | Pathway | Target Lesion | Key Proteins/Complexes | Fidelity | Cell Cycle Phase |
|---|---|---|---|---|---|
| 1. | BER | Oxidized/alkylated bases | DNA glycosylases, APE1, POLβ, XRCC1 | High | All phases |
| 2. | NER | Bulky adducts, UV dimers | XPC, XPA, ERCC1, POLδ/ε | High | G1/S/G2 |
| 3. | MMR | Replication mismatches | MSH2–MSH6, MLH1–PMS2 | High | S/G2 |
| 4. | HR | DSBs (error-free) | MRN complex, BRCA1/2, RAD51 | Very High | S/G2 |
| 5. | NHEJ | DSBs (error-prone) | Ku70/80, DNA-PKcs, XRCC4, LIG4 | Low-Moderate | All phases |




**Figure 1: Schematic of DDR Pathway Interactions**

*(Note: Figure not referenced in numbering, included for visualization only)*

A flowchart illustrating the coordination of DDR pathways in response to various types of DNA damage:

- Top layer: Damage types (e.g., UV, ROS, replication stress).
- Middle layer: Sensors and key DDR proteins.
- Bottom layer: Repair pathways and outcomes (e.g., error-free HR, error-prone NHEJ).

### 2.6 Pathway Crosstalk and Functional Redundancy

Despite their distinct roles, DDR pathways are highly interconnected. Inactivation of one pathway (e.g., HR) may result in reliance on compensatory repair mechanisms (e.g., NHEJ or alt-EJ), underlying the rationale for synthetic lethal targeting in DDR-deficient cancers [19,20].

## 3. Key Pharmacological Modulators of DDR

Therapeutic exploitation of DDR vulnerabilities in cancer has led to the development of several pharmacological agents targeting critical DDR proteins. These drugs act by disrupting DNA repair processes, often inducing synthetic lethality in tumors with pre-existing DDR deficiencies.

### 3.1 PARP Inhibitors (PARPi)

PARP enzymes (PARP1/2) are central to single-strand break (SSB) repair via base excision repair. PARP inhibitors (e.g., Olaparib, niraparib) trap PARP on DNA, converting SSBs into cytotoxic double-strand breaks (DSBs) during replication. This is especially lethal in homologous recombination-deficient (HRD) tumors [21,22].

Four PARP inhibitors are FDA-approved:

- Olaparib (breast, ovarian, pancreatic, prostate cancers)
- Niraparib (ovarian cancer)
- Rucaparib (ovarian, prostate cancers)
- Talazoparib (breast cancer)

### 3.2 ATR and ATM Inhibitors

ATR and ATM are apical DDR kinases activated by replication stress and DSBs, respectively. ATR inhibitors (e.g., ceralasertib, elimusertib) show activity in ATM-deficient tumors, while ATM inhibitors (e.g., AZD0156) sensitize tumors to genotoxic therapies [23,24].

### 3.3 CHK1/CHK2 and WEE1 Inhibitors

CHK1 and CHK2 mediate cell cycle checkpoints downstream of ATR/ATM. CHK1 inhibitors (e.g., prexasertib) abrogate S and G2/M checkpoints, driving replication catastrophe in p53-deficient tumors. WEE1 inhibitors (e.g., adavosertib) similarly override G2/M arrest, enhancing sensitivity to chemotherapy and radiation [25–27].

### 3.4 DNA-PK Inhibitors

DNA-PKcs is crucial for non-homologous end joining (NHEJ). DNA-PK inhibitors (e.g., pepinemab, M3814) are explored in combination with radiotherapy to sensitize DSB repair-deficient tumors [28].

### 3.5 Combination Strategies and Emerging DDR Inhibitors

Combining DDR inhibitors (e.g., PARPi + ATRi) leverages synthetic lethality beyond HRD, targeting compensatory DDR pathways [29]. Novel DDR modulators—including POLθ and RAD52 inhibitors—are also being investigated to address resistance and broaden the therapeutic window [30].

**Table 2: Major DDR-Targeted Agents in Cancer Therapy**

| S. No. | Target | Examples | Mechanism | Clinical Status |
|---|---|---|---|---|
| 1. | PARP | Olaparib, Niraparib | PARP1/2 inhibition, trapping | Approved for HRD cancers |

| | | | | |
|---|---|---|---|---|
| 2. | ATR | Ceralasertib, Elimusertib | Inhibit replication stress response | Phase II/III trials |
| 3. | ATM | AZD0156 | ATM kinase inhibition | Phase I/II trials |
| 4. | CHK1/CHK2 | Prexasertib | Checkpoint abrogation | Phase II trials |
| 5. | WEE1 | Adavosertib (AZD1775) | G2/M checkpoint override | Phase II/III trials |
| 6. | DNA-PK | M3814 (Pepinemab) | Inhibit NHEJ | Phase I/II trials |

### 3.6 Clinical Development Landscape

Numerous DDR inhibitors have advanced into early-phase trials across various cancers, including triple-negative breast cancer (TNBC), prostate cancer, and ovarian cancer. Combination regimens with chemotherapy, immunotherapy, and radiotherapy aim to expand efficacy beyond HR-deficient tumors [31]

## 4. Combination Therapies & Clinical Integration

Given the complexity and redundancy of DDR pathways in cancer, combining DDR inhibitors with other treatment modalities has emerged as a promising strategy to enhance therapeutic efficacy and circumvent resistance.

### 4.1 DDR Inhibitors + Chemotherapy

Combining DDR inhibitors with conventional DNA-damaging chemotherapies amplifies cytotoxic effects by preventing repair of therapy-induced DNA lesions [31]. For example, PARP inhibitors (e.g., Olaparib) have been paired with platinum-based chemotherapy (carboplatin, cisplatin) in ovarian and breast cancer trials, demonstrating synergistic lethality in HR-deficient tumors [32].

However, overlapping toxicities—particularly myelosuppression—necessitate dose adjustments and careful patient monitoring [33].

### 4.2 DDR Inhibitors + Radiotherapy

Radiotherapy induces DNA double-strand breaks (DSBs), which rely on NHEJ and HR for repair. Inhibiting DDR pathways—particularly DNA-PK, ATR, and ATM—sensitizes tumors to radiotherapy, as seen in preclinical models of glioblastoma and head and neck squamous cell carcinoma (HNSCC) [34].

Clinical trials are evaluating DNA-PK inhibitors (e.g., pepinemab) with radiotherapy to overcome radio resistance [35].

### 4.3 DDR Inhibitors + Immunotherapy

Recent studies reveal that DDR inhibitors can potentiate antitumor immunity by:

- Increasing neoantigen load

- Activating the cGAS–STING pathway and Type I interferon responses [36]

This has driven trials combining PARPi or ATR inhibitors with PD-1/PD-L1 checkpoint inhibitors in triple-negative breast cancer (TNBC) and prostate cancer [37].

### 4.4 Triple Combination Strategies

Emerging regimens include DDR inhibitor + chemotherapy + immunotherapy, e.g., Olaparib + paclitaxel + durvalumab in ovarian cancer trials [38].

These triplet strategies aim to overcome resistance mechanisms and broaden therapeutic windows.

**Table 3: Representative DDR Combination Strategies**

| S. No. | Combination Strategy | Mechanism | Clinical Indication | Status |
|---|---|---|---|---|
| 1 | PARPi + Platinum agents | Enhanced SSB to DSB conversion in HRD tumors | Ovarian, breast cancer | FDA-approved |
| 2 | ATRi + Topoisomerase inhibitors | Replication stress targeting | Solid tumors (early trials) | Phase II |
| 3 | DNA-PKi + Radiotherapy | Radiosensitization via impaired DSB repair | Glioblastoma, HNSCC | Phase I/II |
| 4 | PARPi + Anti-PD-1/PD-L1 | DDR-induced immunogenicity | TNBC, prostate cancer | Phase II/III |
| 5 | PARPi + Chemotherapy + ICI | Maximize cytotoxicity and immune activation | Ovarian cancer (triplet trials) | Phase II |

### 4.5 Challenges & Considerations

Combination regimens often intensify hematologic toxicity (anemia, neutropenia), demanding dose optimization [39]. Biomarker-driven patient selection—based on HRD status, TMB, and immune signatures—remains crucial to maximize benefits and minimize adverse effects [40].

## 5. Biomarkers & Patient Stratification

Effective clinical application of DDR-targeted therapies requires precise identification of patients most likely to benefit. This necessitates validated biomarkers that predict sensitivity or resistance to DDR modulators and guide therapeutic decisions.

### 5.1 Homologous Recombination Deficiency (HRD) Testing

The most extensively used biomarker in DDR-targeted treatment is HRD status, reflecting the impairment of homologous recombination (HR) repair mechanisms. HRD can result from BRCA1/2 mutations, but also from alterations in other HR genes (e.g., RAD51C, PALB2) or epigenetic silencing [41]. HRD assays typically

quantify genomic scarring through measures such as loss of heterozygosity (LOH), telomeric allelic imbalance, and large-scale transitions [42].

### 5.2 BRCA1/2 Mutation Status

Both germline and somatic mutations in BRCA1/2 are strong predictive biomarkers for PARP inhibitor sensitivity. Companion diagnostic tests, such as the Foundation One CDx and Myriad my Choice CDx, are FDA-approved to identify eligible patients [43].

### 5.3 ATM, ATR, and MMR Defects

- ATM and ATR mutations sensitize tumors to inhibitors of these kinases, with ATM loss particularly relevant in prostate and hematologic malignancies [44].
- MMR deficiency (dMMR) and microsatellite instability (MSI) predict response to immunotherapy, but also indicate DDR dysregulation, which may potentiate DDR inhibitor synergy [45].

### 5.4 Functional & Dynamic Biomarkers

Dynamic, functional assays are increasingly explored to complement static genetic tests:

- RAD51 foci formation as a real-time indicator of HR competency [46].
- Phosphorylated γH2AX and pRPA levels as pharmacodynamic markers of replication stress and DDR activity [47].

### 5.5 Liquid Biopsies and Emerging Tools

Circulating tumor DNA (ctDNA) and exosomal RNA profiling are promising for monitoring DDR gene alterations and clonal evolution under therapy pressure [48]. Additionally, AI-based models are being developed to integrate genomic and histopathologic data to predict DDR deficiency or resistance patterns [49,50].

**Table 4: Key DDR Biomarkers & Companion Diagnostics**

| S. No. | Biomarker/Test | Associated DDR Pathway | Clinical Application | Status |
|---|---|---|---|---|
| 1. | HRD score (LOH, LST) | HR | PARP inhibitor sensitivity | FDA-approved tests |
| 2. | BRCA1/2 mutations | HR | PARPi eligibility | Germline & somatic |
| 3. | ATM mutations | ATM pathway | ATR inhibitor sensitivity | Trials in prostate cancer |
| 4. | dMMR/MSI | MMR pathway | Immunotherapy response, DDR dysregulation | Approved for ICI |
| 5. | RAD51 foci assay | HR activity | Functional HR proficiency marker | Research tool |

| | | | | |
|---|---|---|---|---|
| 6. | γH2AX, pRPA levels | DDR signaling | Pharmacodynamic readouts | Early-phase trials |
| 7. | ctDNA profiling | All DDR pathways | Dynamic monitoring of DDR alterations | Emerging tool |

## 6. Resistance Mechanisms to DDR Inhibitors

Despite promising clinical outcomes, resistance to DDR-targeted therapies, particularly PARP inhibitors (PARPi), remains a major challenge. Understanding these resistance mechanisms is crucial to developing strategies to sustain clinical responses and improve patient outcomes.

### 6.1 BRCA Reversion Mutations

The most prominent mechanism of acquired resistance involves secondary (reversion) mutations in BRCA1/2 or other HR genes, restoring functional homologous recombination (HR) and negating the synthetic lethality of PARP inhibition [51,52].

### 6.2 Replication Fork Stabilization

Some tumors overcome PARPi cytotoxicity through restoration of replication fork stability. Loss of proteins like PTIP, EZH2, or SLFN11 can stabilize replication forks in HR-deficient contexts, conferring resistance [53,54].

### 6.3 Upregulation of Drug Efflux Pumps

Increased expression of ATP-binding cassette (ABC) transporters, such as ABCB1 (P-glycoprotein), can lower intracellular concentrations of PARPi and reduce drug efficacy [55].

### 6.4 Activation of Alternative Repair Pathways

Cancer cells may upregulate alternative end-joining (alt-EJ) or base excision repair (BER) pathways as compensatory mechanisms to maintain genome stability in the absence of HR [56,57].

### 6.5 Epigenetic Modulation

Reversal of epigenetic silencing of HR genes (e.g., BRCA1 promoter demethylation) can restore HR proficiency and drive resistance [58].

### 6.6 Tumor Microenvironment and Immune Modulation

The immune microenvironment also influences DDR inhibitor efficacy. Suppression of the STING–cGAS pathway or increased PD-L1 expression can dampen the immunogenicity induced by DDR inhibitors, contributing to resistance [59].

**Table 5: Key Resistance Mechanisms to DDR Inhibitors**

| S. No. | Resistance Mechanism | Molecular Basis | Clinical/Preclinical Evidence |
|---|---|---|---|

| | | |
|---|---|---|
| 1. BRCA reversion mutations | Restoration of HR by second-site mutations | Detected in recurrent ovarian, breast cancer [51,52] |
| 2. Replication fork stabilization | Loss of fork degradation factors (PTIP, EZH2) | Preclinical models [53,54] |
| 3. Drug efflux upregulation | ABCB1 overexpression | Preclinical and clinical observations [55] |
| 4. Alternative repair pathway activation | POLθ-mediated alt-EJ, RAD52-dependent repair | Preclinical evidence [56,57] |
| 5. Epigenetic reprogramming | Demethylation of BRCA1, RAD51 | Clinical samples with resistance [58] |
| 6. Immune evasion | cGAS–STING suppression, PD-L1 overexpression | Immune editing in PARPi-resistant tumors [59] |

### 6.7 Strategies to Overcome Resistance

Emerging strategies to counter resistance include:

- Combination therapy (e.g., PARPi + ATR/CHK1 inhibitors)
- Targeting replication fork protection (e.g., EZH2 inhibitors)
- Modulating the immune environment (e.g., combining DDRi with PD-1/PD-L1 inhibitors) [60].

## 7. Future Directions & Conclusion

The rapid expansion of DDR-targeted therapies has reshaped the landscape of precision oncology. Nonetheless, several challenges remain in translating DDR modulation into broader clinical success and durable responses.

### 7.1 Emerging DDR Targets and Combinatorial Strategies

Future DDR therapies will expand beyond PARP inhibition to target synthetic lethal pairs such as ATR–CHK1 and POLθ–HRD. Preclinical studies highlight that dual DDR blockade can overcome resistance and extend efficacy beyond HR-deficient cancers [61]. Additionally, DDR inhibitors combined with immunotherapy—capitalizing on the immunostimulatory effects of DNA damage—represent a promising avenue under clinical investigation [62].

### 7.2 Biomarker and Patient Stratification Innovations

Accurate biomarker-driven selection remains essential to optimize DDR-targeted therapies. Advances in liquid biopsies (ctDNA) and AI-based histopathologic models are enabling dynamic assessment of DDR status and resistance development [63,64]. These tools may allow real-time patient stratification and adaptive treatment strategies.

### 7.3 Mitigating Toxicity and Selectivity Challenges

On-target toxicities, especially hematologic suppression, limit the feasibility of DDR combination therapies. Approaches under evaluation include intermittent dosing regimens and tumor-selective delivery methods (e.g., nanoparticles, antibody–drug conjugates) to reduce adverse effects while maintaining therapeutic potency [65].

### 7.4 Challenges in Clinical Translation

Key challenges for clinical implementation include:

- Inconsistent HRD testing platforms across tumor types
- Limited biomarker validation in rare cancers
- Need for tumor-agnostic trials to streamline DDR drug approvals [66]

Addressing these gaps requires collaborative, multidisciplinary efforts integrating genomic profiling, functional imaging, and adaptive trial designs.

### 7.5 Conclusion

The pharmacological modulation of DDR pathways has emerged as a cornerstone of precision cancer therapy, offering significant promise in HR-deficient and genomically unstable tumors. However, resistance development, toxicity management, and biomarker-based patient selection remain formidable hurdles.

Future research will likely focus on synthetic lethality beyond PARP, immune-modulatory combinations, and AI-driven biomarker discovery. Through these efforts, DDR-targeted strategies are poised to play an increasingly central role in the evolving landscape of personalized oncology.

## 8. References

1. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. *Cell*, 144(5), 646–674.
2. Jackson, S. P., & Bartek, J. (2009). The DNA-damage response in human biology and disease. *Nature*, 461(7267), 1071–1078.
3. Ciccia, A., & Elledge, S. J. (2010). The DNA damage response: Making it safe to play with knives. *Molecular Cell*, 40(2), 179–204.
4. Lord, C. J., & Ashworth, A. (2012). The DNA damage response and cancer therapy. *Nature*, 481(7381), 287–294.
5. Jeggo, P. A., et al. (2011). DNA repair and cancer: New therapeutic opportunities. *Cancer Biology & Therapy*, 12(11), 978–987.
6. Negrini, S., Gorgoulis, V. G., & Halazonetis, T. D. (2010). Genomic instability—An evolving hallmark of cancer. *Nature Reviews Molecular Cell Biology*, 11(3), 220–228.
7. Bryant, H. E., et al. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature*, 434(7035), 913–917.

8. Yap, T. A., et al. (2020). DNA damage response-targeted therapy: Advances and challenges. *Nature Reviews Clinical Oncology*, 17(3), 135–149.
9. Fong, P. C., et al. (2009). Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. *New England Journal of Medicine*, 361(2), 123–134.
10. O'Connor, M. J. (2015). Targeting the DNA damage response in cancer. *Molecular Cell*, 60(4), 547–560.
11. Krokan, H. E., & Bjørås, M. (2013). Base excision repair. *Cold Spring Harbor Perspectives in Biology*, 5(4), a012583.
12. Sancar, A. (1996). DNA excision repair. *Annual Review of Biochemistry*, 65, 43–81.
13. Marteijn, J. A., et al. (2014). Understanding NER. *Nature Reviews Molecular Cell Biology*, 15(7), 465–481.
14. Jiricny, J. (2006). Mismatch repair: From bacteria to cancer. *Nature Reviews Molecular Cell Biology*, 7(5), 335–346.
15. Li, G. M. (2008). Mechanisms and functions of DNA mismatch repair. *Cell Research*, 18(1), 85–98.
16. San Filippo, J., et al. (2008). Mechanism of homologous recombination. *Annual Review of Biochemistry*, 77, 229–257.
17. Moynahan, M. E., & Jasin, M. (2010). Mitotic HR maintains genomic stability. *Nature Reviews Molecular Cell Biology*, 11(3), 196–207.
18. Chang, H. H. Y., et al. (2017). Non-homologous DNA end joining and alternative pathways. *Nature Reviews Molecular Cell Biology*, 18(8), 495–506.
19. Jeggo, P. A., et al. (2011). Role of DNA repair in genome stability. *Nature Reviews Genetics*, 12(12), 801–812.
20. D'Andrea, A. D. (2018). Mechanisms of DDR inhibitor sensitivity and resistance. *DNA Repair*, 71, 172–176.
21. Lord, C. J., & Ashworth, A. (2017). PARP inhibitors: Synthetic lethality in the clinic. *Science*, 355(6330), 1152–1158.
22. Moore, K., et al. (2018). Maintenance niraparib in platinum-sensitive, recurrent ovarian cancer. *NEJM*, 377(15), 1392–1400.
23. Foote, K. M., et al. (2018). ATR inhibition as a cancer therapeutic strategy. *Nature Reviews Drug Discovery*, 17(10), 803–821.
24. Sun, Y., et al. (2022). ATM and DNA-PK inhibition in oncology. *Clinical Cancer Research*, 28(5), 1005–1015.
25. Bryant, H. E., et al. (2021). CHK1 and WEE1 as therapeutic targets. *Molecular Cell Oncology*, 8(3), e197–203.
26. Do, K., et al. (2015). Phase I study of CHK1 inhibitor prexasertib. *Journal of Clinical Oncology*, 33(15), 2504–2504.
27. O'Carrigan, B., et al. (2016). Adavosertib plus carboplatin in solid tumors. *Journal of Clinical Oncology*, 34(36), 4354–4361.

28. Zenke, F. T., et al. (2020). DNA-PK inhibition for radiosensitization. *Cancer Research*, 80(15), 2964–2974.
29. Yap, T. A., et al. (2021). Strategies for DDR combination therapy. *Nature Reviews Clinical Oncology*, 18(8), 478–495.
30. Ceccaldi, R., et al. (2015). DNA polymerase θ promotes alt-EJ in HR-deficient cells. *Nature*, 518(7539), 254–257.
31. Kaye, S. B., et al. (2012). Combining olaparib with chemotherapy in ovarian cancer. *Journal of Clinical Oncology*, 30(12), 1340–1346.
32. Moore, K., et al. (2018). Maintenance niraparib in platinum-sensitive ovarian cancer. *NEJM*, 377(15), 1392–1400.
33. Oza, A. M., et al. (2015). Dose-limiting toxicities in PARPi-chemotherapy trials. *Lancet Oncology*, 16(1), 87–97.
34. Goodwin, J. F., et al. (2021). Radiosensitization by DDR inhibitors. *Cancer Research*, 81(9), 2347–2357.
35. Zenke, F. T., et al. (2020). DNA-PK inhibition to improve radiotherapy. *Cancer Research*, 80(15), 2964–2974.
36. Harding, S. M., et al. (2017). DNA damage-driven immune activation. *Nature Communications*, 8, 14090.
37. Domchek, S. M., et al. (2018). Combining olaparib with durvalumab. *JCO*, 36(15_suppl), 1010–1010.
38. Konstantinopoulos, P. A., et al. (2019). Triplet regimens in ovarian cancer. *Gynecologic Oncology*, 154(1), 63–68.
39. Drew, Y., et al. (2016). Myelosuppression in DDR combination therapies. *Annals of Oncology*, 27(9), 1441–1447.
40. Yap, T. A., et al. (2021). Strategies for DDR combination therapy. *Nature Reviews Clinical Oncology*, 18(8), 478–495.
41. Telli, M. L., et al. (2016). Homologous recombination deficiency as a predictive biomarker. *Cancer Discovery*, 6(9), 936–943.
42. Abkevich, V., et al. (2012). Patterns of LOH and genomic scarring in HRD. *Cancer Research*, 72(21), 5565–5575.
43. Mateo, J., et al. (2020). FDA approval of HRD testing in prostate cancer. *Clinical Cancer Research*, 26(13), 3337–3341.
44. de Bono, J., et al. (2020). ATR inhibitor ceralasertib in ATM-deficient tumors. *Nature Medicine*, 26(8), 1395–1401.

45. Le, D. T., et al. (2015). PD-1 blockade in mismatch repair-deficient tumors. *New England Journal of Medicine*, 372(26), 2509–2520.

46. Cruz, C., et al. (2018). RAD51 foci as functional biomarkers in ovarian cancer. *Clinical Cancer Research*, 24(19), 4482–4493.

47. Lin, Z. P., et al. (2014). Pharmacodynamic markers for DDR inhibitors. *Clinical Cancer Research*, 20(17), 4373–4383.

48. Meric-Bernstam, F., et al. (2019). ctDNA in DDR-targeted trials. *Clinical Cancer Research*, 25(18), 5671–5678.

49. Schaumberg, A. J., et al. (2020). AI-based prediction of HRD from histopathology. *Nature Communications*, 11(1), 5594.

50. Abida, W., et al. (2019). Biomarker-driven DDR therapy in prostate cancer. *Journal of Clinical Oncology*, 37(4), 318–327.

51. Edwards, S. L., et al. (2008). Resistance to therapy caused by intragenic deletion in BRCA2. *Nature*, 451(7182), 1111–1115.

52. Christie, E. L., et al. (2017). Reversion of BRCA1/2 mutations in ovarian cancer. *JCO Precision Oncology*, 1, 1–9.

53. Rondinelli, B., et al. (2017). EZH2 promotes replication fork stability in BRCA2-deficient cells. *Nature Communications*, 8(1), 1390.

54. Murai, J., et al. (2016). SLFN11 blocks replication stress and confers PARP inhibitor sensitivity. *Nature Communications*, 7, 12248.

55. Rottenberg, S., et al. (2008). Impact of drug efflux transporters on PARP inhibitor resistance. *PNAS*, 105(50), 17079–17084.

56. Ceccaldi, R., et al. (2015). DNA polymerase θ promotes alt-EJ in BRCA-deficient cells. *Nature*, 518(7539), 254–257.

57. Hanamshet, K., et al. (2016). RAD52 as an alternative repair pathway. *Oncotarget*, 7(7), 6736–6747.

58. Kondrashova, O., et al. (2018). Methylation reversal restores HR and confers resistance. *Clinical Cancer Research*, 24(19), 4552–4561.

59. Pantelidou, C., et al. (2019). PARP inhibition activates STING-dependent immune response. *Cancer Discovery*, 9(6), 722–737.

60. Yap, T. A., et al. (2021). Strategies to overcome DDR inhibitor resistance. *Nature Reviews Clinical Oncology*, 18(8), 478–495.

61. O'Neil, N. J., et al. (2017). Synthetic lethality in precision oncology. *Nature Reviews Genetics*, 18(10), 613–623.

62. Mouw, K. W., et al. (2017). DNA damage and immune checkpoint synergy. *Nature Reviews Cancer*, 17(12), 779–792.

63. Meric-Bernstam, F., et al. (2019). ctDNA-based DDR monitoring. *Clinical Cancer Research*, 25(18), 5671–5678.

64. Schaumberg, A. J., et al. (2020). AI prediction of DDR deficiency. *Nature Communications*, 11(1), 5594.

65. Drew, Y., et al. (2016). Managing toxicities in DDR inhibitor combinations. *Annals of Oncology*, 27(9), 1441–1447.

66. Yap, T. A., et al. (2021). Clinical trial design for DDR-targeted therapies. *Nature Reviews Clinical Oncology*, 18(8), 478–495.